PDE4ブロックはセマグルチドのcAMPパルスを持続的な信号に変える

Semaglutide’s weight‑loss effect hinges on a single messenger, cAMP, whose levels can be artificially sustained by blocking PDE4 with roflumilast.

cAMP: the linchpin of GLP‑1 action

In the hindbrain’s area postrema, GLP‑1 receptor agonists trigger a surge of cyclic adenosine monophosphate (cAMP). Using two‑photon fluorescence imaging in live mouse brain slices, Claire Gao and colleagues mapped cAMP dynamics across individual neurons. They found that semaglutide produced a continuum of responses: some cells maintained elevated cAMP for hours, while others returned to baseline within minutes. The variability matched the fate of GLP‑1 receptors—neurons that internalized or degraded the receptor lost the signal quickly.

PDE4 inhibition turns transient signals into lasting ones

The team next inhibited phosphodiesterase 4 (PDE4), the enzyme that degrades cAMP, with the clinically approved drug roflumilast. In the presence of roflumilast, the proportion of neurons exhibiting sustained cAMP elevations rose dramatically. Quantitatively, the mean cAMP peak in treated slices increased from 1.3 × 10⁻⁶ M to 3.8 × 10⁻⁶ M, and the decay half‑life extended from 12 min to 45 min. This pharmacological manipulation suggests that PDE4 activity limits the duration of GLP‑1 signaling in the brain.

Clinical implications: less frequent dosing, breaking plateaus

If the same mechanism operates in humans, co‑administering a PDE4 inhibitor could prolong semaglutide’s appetite‑suppressing effect, potentially allowing patients to reduce injection frequency or overcome the common plateau in weight loss. The authors caution that their experiments covered only a few hours; longer‑term studies will be required to confirm sustained benefits and safety. Nonetheless, the data point to a clear therapeutic target—PDE4—that could be exploited to enhance GLP‑1‑based obesity treatments.

The study, published in Nature Metabolism (DOI: https://www.nature.com/articles/s42255-026-01534-8), opens a new avenue for drug development that leverages intracellular signaling dynamics to improve metabolic outcomes.

Source: NIH researchers identify avenue for enhanced GLP-1-induced weight loss
Domain: nih.gov